Drug for Lou Gehrig’s promising for Skin Melanoma’s
A Rutgers Professor has found that a drug that has been approved by the US FDA for treating Lou Gehrig’s disease has promising results by slowing the growth of Skin Melanoma’s, the most deadly form of skin cancer. The study is already in phase 0 clinical trials and the results have been promising so far. The active ingredient rilozole under the Rilutek brand has been approved by the US FDA for human trials according to Dr. James Goydos a surgical oncologist at the Cancer Institute of New Jersey. Skin melanomas are not very responsive to chemotherapy like other forms of cancer and the rate of occurrence has been doubled in the past 20 years. This is alarming for not much is available for the treatment of the debilitating disease that when allowed to spread can become lethal.